



# Pulmonary Fibrosis Foundation

Financial Statements  
Years Ended June 30, 2021 and 2020

# **Pulmonary Fibrosis Foundation**

---

Financial Statements  
Years Ended June 30, 2021 and 2020

# Pulmonary Fibrosis Foundation

## Contents

---

Independent Auditor's Report	3-4
<b>Financial Statements</b>	
Statements of Financial Position as of June 30, 2021 and 2020	6
Statements of Activities and Changes in Net Assets for the Years Ended June 30, 2021 and 2020	7-8
Statements of Functional Expenses for the Years Ended June 30, 2021 and 2020	9-10
Statements of Cash Flows for the Years Ended June 30, 2021 and 2020	11
Notes to Financial Statements	12-27



## Independent Auditor's Report

The Board of Directors  
Pulmonary Fibrosis Foundation  
Chicago, Illinois

### ***Opinion***

We have audited the financial statements of Pulmonary Fibrosis Foundation (the Organization), which comprise the statements of financial position as of June 30, 2021 and 2020, and the related statements of activities and changes in net assets, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Pulmonary Fibrosis Foundation as of June 30, 2021 and 2020, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

### ***Emphasis of Matter - Revenue from Contracts with Customers***

As more fully described in Note 1 to the financial statements, on July 1, 2020 the Organization adopted new accounting guidance related to revenue from contracts with customers. Our opinion is not modified with respect to this matter.

### ***Basis for Opinion***

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Organization and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### ***Responsibilities of Management for the Financial Statements***

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued.



### ***Auditor's Responsibilities for the Audit of the Financial Statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

BDO USA, LLP

February 16, 2022

## Financial Statements

---

# Pulmonary Fibrosis Foundation

## Statements of Financial Position

<i>June 30,</i>	2021	2020
<b>Assets</b>		
<b>Current Assets</b>		
Cash and cash equivalents	\$ 6,390,586	\$ 5,154,506
Accounts receivable	463,106	1,628
Contributions receivable	28,296	30,718
Pledges receivable	30,000	25,000
Contract receivable	1,040,366	32,369
Other receivables - current	-	375,000
Prepaid expenses and other assets	507,279	137,343
<b>Total Current Assets</b>	<b>8,459,633</b>	<b>5,756,564</b>
<b>Property and Equipment, Net</b>	<b>45,371</b>	<b>42,990</b>
<b>Other Assets</b>		
Other receivables - non-current	375,000	-
Investments	5,549,485	4,863,723
Deposits	56,631	56,631
Intangibles, net	259,472	143,563
Goodwill, net	-	29,333
<b>Total Other Assets</b>	<b>6,240,588</b>	<b>5,093,250</b>
<b>Total Assets</b>	<b>\$ 14,745,592</b>	<b>\$ 10,892,804</b>
<b>Liabilities and Net Assets</b>		
<b>Current Liabilities</b>		
Accounts payable	\$ 760,853	\$ 220,792
Grants payable	337,500	300,000
Accrued liabilities	1,316,491	1,302,965
Deferred revenue	2,437,790	1,207,629
Current portion of capital lease obligation	-	3,288
<b>Total Current Liabilities</b>	<b>4,852,634</b>	<b>3,034,674</b>
<b>Long-Term Liabilities</b>		
Paycheck Protection Program loan	580,675	560,300
<b>Total Long-Term Liabilities</b>	<b>580,675</b>	<b>560,300</b>
<b>Total Liabilities</b>	<b>5,433,309</b>	<b>3,594,974</b>
<b>Net Assets</b>		
Without donor restrictions	6,584,930	4,012,393
With donor restrictions	2,727,353	3,285,437
<b>Total Net Assets</b>	<b>9,312,283</b>	<b>7,297,830</b>
<b>Total Liabilities and Net Assets</b>	<b>\$ 14,745,592</b>	<b>\$ 10,892,804</b>

*See accompanying notes to financial statements.*

# Pulmonary Fibrosis Foundation

## Statements of Activities and Changes in Net Assets

Year ended June 30, 2021

	Without Donor Restrictions	With Donor Restrictions	Total
<b>Revenues, Gains, and Other Support</b>			
Public support:			
Contributions	\$ 3,264,024	\$ 161,897	\$ 3,425,921
In-kind contributions	916	-	916
Sponsorship	725,907	884,750	1,610,657
Special events	814,660	224,216	1,038,876
<b>Total Public Support</b>	<b>4,805,507</b>	<b>1,270,863</b>	<b>6,076,370</b>
Program service fees:			
Program service fees	2,908,697	-	2,908,697
<b>Total Program Service Fees</b>	<b>2,908,697</b>	<b>-</b>	<b>2,908,697</b>
Other revenues and support:			
Gain from forgiveness of Paycheck Protection Program loan	560,300	-	560,300
Miscellaneous income	23,649	-	23,649
Loss on disposal of fixed assets	(25,321)	-	(25,321)
<b>Total Other Revenues and Support</b>	<b>558,628</b>	<b>-</b>	<b>558,628</b>
Investment income:			
Interest and dividends	152,919	-	152,919
Realized loss on investments	(61,981)	-	(61,981)
Unrealized gain on investments	640,807	-	640,807
<b>Total Investment Income</b>	<b>731,745</b>	<b>-</b>	<b>731,745</b>
<b>Total Revenue, Gains, and Other Support, before net assets released from restriction</b>	<b>9,004,577</b>	<b>1,270,863</b>	<b>10,275,440</b>
<b>Net Assets Released from Restriction</b>	<b>1,828,947</b>	<b>(1,828,947)</b>	<b>-</b>
<b>Total Revenues, Gains, and Other Support</b>	<b>10,833,524</b>	<b>(558,084)</b>	<b>10,275,440</b>
<b>Expenses</b>			
Program	6,172,855	-	6,172,855
Management and general	1,243,132	-	1,243,132
Fundraising	1,594,896	-	1,594,896
<b>Total Expenses</b>	<b>9,010,883</b>	<b>-</b>	<b>9,010,883</b>
<b>Change in Net Assets</b>	<b>1,822,641</b>	<b>(558,084)</b>	<b>1,264,557</b>
<b>Net Assets, beginning of year, as previously reported</b>	<b>4,012,393</b>	<b>3,285,437</b>	<b>7,297,830</b>
<b>Cumulative Effect Adjustment of Adopting ASC 606 on July 1, 2020 (Note 1)</b>	<b>749,896</b>	<b>-</b>	<b>749,896</b>
<b>Net Assets, beginning of year, as adjusted</b>	<b>4,762,289</b>	<b>3,285,437</b>	<b>8,047,726</b>
<b>Net Assets, end of year</b>	<b>\$ 6,584,930</b>	<b>\$ 2,727,353</b>	<b>\$ 9,312,283</b>

See accompanying notes to financial statements.



# Pulmonary Fibrosis Foundation

## Statements of Activities and Changes in Net Assets

*Year ended June 30, 2020*

	Without Donor Restrictions	With Donor Restrictions	Total
<b>Revenues, Gains, and Other Support</b>			
Public support:			
Contributions	\$ 4,692,292	\$ 573,956	\$ 5,266,248
In-kind contributions	335	-	335
Sponsorship	318,995	1,749,099	2,068,094
Special events	1,012,849	146,853	1,159,702
<b>Total Public Support</b>	<b>6,024,471</b>	<b>2,469,908</b>	<b>8,494,379</b>
Program service fees:			
Program service fees	2,117,097	-	2,117,097
Registrations	431,049	-	431,049
<b>Total Program Service Fees</b>	<b>2,548,146</b>	<b>-</b>	<b>2,548,146</b>
Other revenues:			
Sale of goods	11,069	-	11,069
Miscellaneous	2,002	-	2,002
<b>Total Other Revenues</b>	<b>13,071</b>	<b>-</b>	<b>13,071</b>
Investment income:			
Interest and dividends	257,033	-	257,033
Realized gain on investments	36,051	-	36,051
Unrealized loss on investments	(176,340)	-	(176,340)
<b>Total Investment Income</b>	<b>116,744</b>	<b>-</b>	<b>116,744</b>
<b>Total Revenues, Gains, and Other Support, before net assets released from restriction</b>	<b>8,702,432</b>	<b>2,469,908</b>	<b>11,172,340</b>
<b>Net Assets Released from Restriction</b>	<b>3,377,181</b>	<b>(3,377,181)</b>	<b>-</b>
<b>Total Revenues, Gains, and Other Support</b>	<b>12,079,613</b>	<b>(907,273)</b>	<b>11,172,340</b>
<b>Expenses</b>			
Program	9,110,969	-	9,110,969
Management and general	1,103,628	-	1,103,628
Fundraising	1,723,662	-	1,723,662
<b>Total Expenses</b>	<b>11,938,259</b>	<b>-</b>	<b>11,938,259</b>
<b>Change in Net Assets</b>	<b>141,354</b>	<b>(907,273)</b>	<b>(765,919)</b>
<b>Net Assets, beginning of year</b>	<b>3,871,039</b>	<b>4,192,710</b>	<b>8,063,749</b>
<b>Net Assets, end of year</b>	<b>\$ 4,012,393</b>	<b>\$ 3,285,437</b>	<b>\$ 7,297,830</b>

*See accompanying notes to financial statements.*

# Pulmonary Fibrosis Foundation

## Statements of Functional Expenses

Year ended June 30, 2021

	Program									Support			
	Education	Legislative Advocacy	Outreach and Awareness	Care Center Network	PFF Patient Registry	PFF Summit	Program Support	Research Grants	Support Groups	Total Program	Management and General	Fundraising	Total
Salaries and wages	\$ 406,076	\$ 131,615	\$ 373,089	\$ 160,508	\$ 330,185	\$ 136,903	\$ 193,507	\$ 71,715	\$ 66,108	\$ 1,869,706	\$ 777,912	\$ 1,017,211	\$ 3,664,829
Employee benefits	29,474	7,175	28,180	16,732	26,920	10,073	17,994	3,760	6,945	147,253	94,678	92,410	334,341
Payroll taxes	24,780	6,032	22,850	14,067	22,633	8,469	15,129	3,161	5,839	122,960	42,321	76,561	241,842
Accounting	3,209	781	2,959	1,822	2,931	1,097	1,959	409	756	15,923	9,764	9,916	35,603
Advertising	19,997	-	20,477	54,624	-	-	22,448	-	450	117,996	-	500	118,496
Bank fees	-	-	-	-	-	-	821	-	-	821	179	348	1,348
Consulting	357,988	120,000	219,534	82,133	833,023	19,027	236,771	15,083	11,897	1,895,456	77,656	37,579	2,010,691
Depreciation and amortization	4,487	930	9,022	2,168	3,489	1,306	25,649	487	900	48,438	6,438	11,802	66,678
Dues and subscriptions	12,497	16,100	1,956	650	-	-	5,602	-	1,716	38,521	9,411	-	47,932
Event expense	5,289	-	31,346	14,441	41,526	-	-	-	4,053	96,655	257	46,488	143,400
Grants	-	-	-	2,500	-	-	-	288,500	11,895	302,895	-	-	302,895
Insurance	4,125	1,004	3,804	2,342	3,768	1,410	2,518	526	972	20,469	8,529	12,745	41,743
Internet service	1,506	367	1,389	855	1,376	515	920	192	355	7,475	2,539	4,654	14,668
Legal	2,138	-	18,169	5,975	12,281	2,453	850	203	-	42,069	12,348	4,652	59,069
Meetings and conferences	532	129	490	302	485	182	368	68	125	2,681	896	1,642	5,219
Miscellaneous	836	203	771	474	763	286	1,886	107	197	5,523	6,208	9,046	20,777
Occupancy	631	154	582	358	576	216	385	80	149	3,131	2,457	1,949	7,537
Office supplies	259	68	557	259	554	89	3,529	33	61	5,409	1,374	2,610	9,393
Outside services	100,267	-	35,461	100	753,713	-	24,742	-	1,850	916,133	114,792	4,806	1,035,731
Postage	52,785	-	-	-	-	-	17,491	-	-	70,276	3,104	30,326	103,706
Printing	16,539	-	-	-	27,390	-	15,283	-	-	59,212	-	43,171	102,383
Processing fees	1,674	408	1,544	950	1,529	572	1,022	214	394	8,307	3,350	40,571	52,228
Rent	25,746	6,267	23,740	14,615	23,514	8,799	15,718	3,284	6,067	127,750	43,394	79,543	250,687
Shop PFF merchandise	126,091	-	-	-	-	-	-	-	-	126,091	4,418	-	130,509
Software subscriptions	11,539	1,555	7,589	39,775	5,833	2,183	14,722	11,872	10,068	105,136	10,904	56,830	172,870
Telephone	2,897	705	2,671	1,644	2,646	990	1,768	369	683	14,373	6,569	8,949	29,891
Travel	-	-	2,196	-	-	-	-	-	-	2,196	3,634	587	6,417
<b>Total Functional Expenses</b>	<b>\$ 1,211,362</b>	<b>\$ 293,493</b>	<b>\$ 808,376</b>	<b>\$ 417,294</b>	<b>\$ 2,095,135</b>	<b>\$ 194,570</b>	<b>\$ 621,082</b>	<b>\$ 400,063</b>	<b>\$ 131,480</b>	<b>\$ 6,172,855</b>	<b>\$ 1,243,132</b>	<b>\$ 1,594,896</b>	<b>\$ 9,010,883</b>

See accompanying notes to financial statements.

# Pulmonary Fibrosis Foundation

## Statements of Functional Expenses

Year ended June 30, 2020

	Program										Support			
	Education	Legislative Advocacy	Outreach and Awareness	Patient Communication Center	PFF Care Center Network	PFF Patient Registry	PFF Summit	Program Support	Research Grants	Support Groups	Total Program	Management and General	Fundraising	Total
Salaries and wages	\$ 208,038	\$ 137,064	\$ 263,966	\$ 56,451	\$ 199,959	\$ 283,228	\$ 192,608	\$ 300,952	\$ 76,037	\$ 93,100	\$ 1,811,403	\$ 629,927	\$ 1,001,750	\$ 3,443,080
Employee benefits	22,116	7,544	20,510	8,087	12,456	21,704	14,961	20,236	4,002	9,098	140,714	82,411	94,767	317,892
Payroll taxes	16,864	5,739	14,401	6,167	9,444	17,054	11,407	15,203	3,052	6,937	106,268	56,745	72,254	235,267
Accounting	2,180	741	2,135	797	1,220	1,930	1,475	1,967	395	897	13,737	5,933	9,089	28,759
Advertising	8,019	-	2,384	-	43,605	-	-	109,611	-	2,384	166,003	-	200	166,203
Bank fees	-	-	-	-	-	-	-	939	-	-	939	229	429	1,597
Consulting	135,011	195,023	2,004,026	-	141,395	654,959	52,591	337,015	29,103	26,118	3,575,241	49,363	60,387	3,684,991
Depreciation and amortization	2,780	946	2,723	1,017	1,557	2,462	1,880	12,711	503	1,144	27,723	16,281	11,870	55,874
Dues and subscriptions	14,182	1,499	9,443	-	779	2,047	-	4,590	-	3,042	35,582	11,272	440	47,294
Event expense	41,388	-	15,411	-	45,648	651	755,477	482	-	1,028	860,085	15,331	148,937	1,024,353
Grants	750	-	-	-	-	-	-	-	296,189	45,924	342,863	-	-	342,863
Insurance	3,874	1,318	3,794	1,417	2,169	3,431	2,620	3,493	701	1,594	24,411	10,348	16,514	51,273
Interest expense	-	-	-	-	-	-	-	-	-	-	-	2,036	-	2,036
Internet service	1,113	379	1,090	407	623	986	753	1,004	201	458	7,014	3,031	4,751	14,796
Legal	90	315	22,275	-	2,610	4,320	765	11,160	3,960	-	45,495	24,654	1,125	71,274
Meetings and conferences	387	478	379	141	282	666	262	1,051	70	159	3,875	2,567	2,100	8,542
Miscellaneous	237	81	232	87	133	210	160	2,087	43	98	3,368	7,338	6,830	17,536
Occupancy	480	163	470	176	269	425	325	433	87	198	3,026	1,307	2,044	6,377
Office supplies	493	80	231	86	385	209	1,841	8,345	1,815	97	13,582	2,368	7,504	23,454
Outside services	6,090	125	21,525	-	-	918,076	74,750	20,900	-	4,016	1,045,482	78,095	2,200	1,125,777
Postage	15,671	-	490	132	-	6,798	3,042	14,693	-	36	40,862	3,342	18,585	62,789
Printing	44,337	-	695	-	-	27,958	4,090	31,199	-	608	108,887	100	27,606	136,593
Processing fees	1,174	400	1,182	429	657	1,040	794	1,059	212	483	7,430	3,534	53,620	64,584
Rent	18,955	6,451	18,565	6,932	10,614	16,790	12,822	17,090	3,430	7,797	119,446	50,129	81,047	250,622
Shop PFF merchandise	-	-	-	-	-	-	-	-	-	136	136	5,642	-	5,778
Software subscriptions	8,300	14,564	4,927	1,466	33,820	3,550	2,710	14,707	9,773	2,401	96,218	9,368	50,620	156,206
Telephone	2,108	717	2,094	771	1,180	1,867	1,426	1,901	382	867	13,313	7,883	9,198	30,394
Travel	32,295	14,138	127,216	-	52,803	167,471	65,104	21,863	2,178	14,798	497,866	24,394	39,795	562,055
<b>Total Functional Expenses</b>	<b>\$ 586,932</b>	<b>\$ 387,765</b>	<b>\$ 2,540,164</b>	<b>\$ 84,563</b>	<b>\$ 561,608</b>	<b>\$ 2,137,832</b>	<b>\$ 1,201,863</b>	<b>\$ 954,691</b>	<b>\$ 432,133</b>	<b>\$ 223,418</b>	<b>\$ 9,110,969</b>	<b>\$ 1,103,628</b>	<b>\$ 1,723,662</b>	<b>\$ 11,938,259</b>

See accompanying notes to financial statements.

# Pulmonary Fibrosis Foundation

## Statements of Cash Flows

<i>Year ended June 30,</i>	2021	2020
<b>Cash Flows from Operating Activities</b>		
Change in net assets	\$ 1,264,557	\$ (765,919)
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:		
Depreciation and amortization	66,678	55,874
Loss on disposal of fixed assets	1,488	-
Loss on disposal of goodwill	23,833	-
Realized loss (gain) on investments	61,981	(36,051)
Unrealized (gain) loss on investments	(640,807)	176,340
Donated securities	(5,808)	(2,845,252)
Deferred rent	15,259	28,907
Gain on forgiveness of Paycheck Protection loan	(560,300)	-
Changes in operating assets and liabilities:		
Accounts receivable	(461,478)	96,020
Contract receivable	(1,007,997)	-
Contributions receivable	2,422	5,857
Pledges receivable	(5,000)	725,000
Sponsorships receivable	-	250,000
Prepaid expenses	(369,936)	86,164
Accounts payable	540,061	74,273
Grants payable	37,500	195,689
Accrued liabilities	(1,733)	29,542
Deferred revenue	1,980,057	(119,677)
<b>Net Cash Provided by (Used in) Operating Activities</b>	<b>940,777</b>	<b>(2,043,233)</b>
<b>Cash Flows from Investing Activities</b>		
Proceeds from sale of investments	372,816	7,233,518
Purchases of investments	(473,944)	(4,682,248)
Proceeds from sale of property and equipment	151	1,962
Purchases of property and equipment	(31,822)	(11,905)
Purchases of intangibles	(149,285)	(91,984)
<b>Net Cash Provided by (Used in) Investing Activities</b>	<b>(282,084)</b>	<b>2,449,343</b>
<b>Cash Flows from Financing Activities</b>		
Proceeds from Paycheck Protection Program loan	580,675	560,300
Repayment of capital lease obligation	(3,288)	(9,388)
<b>Net Cash Provided by Financing Activities</b>	<b>577,387</b>	<b>550,912</b>
<b>Net Increase in Cash and Cash Equivalents</b>	<b>1,236,080</b>	<b>957,022</b>
<b>Cash and Cash Equivalents, beginning of year</b>	<b>5,154,506</b>	<b>4,197,484</b>
<b>Cash and Cash Equivalents, end of year</b>	<b>\$ 6,390,586</b>	<b>\$ 5,154,506</b>
<b>Supplemental Disclosure of Cash Flow Information</b>		
Cash paid during the year for interest	\$ -	\$ 2,036

*See accompanying notes to financial statements.*

# Pulmonary Fibrosis Foundation

## Notes to Financial Statements

---

### 1. Summary of Significant Accounting Policies

#### *Nature of Activities*

Our mission is to mobilize people and resources to provide access to high-quality care and lead research for a cure so that people with pulmonary fibrosis (PF) will live longer, healthier lives. By actively engaging the pulmonary fibrosis community, the Pulmonary Fibrosis Foundation (PFF or the Organization) has developed essential programs for patients, caregivers, and healthcare professionals to give them a greater understanding of PF and support while living with the disease.

#### *Basis of Presentation*

The accompanying financial statements are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), as recommended in the American Institute of Certified Public Accountant's Audit and Accounting Guide for Not-for-Profit Organizations.

#### *Cash and Cash Equivalents*

The Organization considers highly liquid investments with maturities of three months or less as cash equivalents.

#### *Use of Estimates*

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

#### *Investments*

Investments in marketable securities and mutual funds are reported at fair value based upon market quotations. Donated investments are reflected as contributions at their fair values at date of receipt. There were donated investments of \$5,808 and \$2,845,252 for the years ended June 30, 2021 and 2020, respectively. The total stock donations in the prior fiscal year include \$2,685,930 from a donor that utilized stock as a funding mechanism in lieu of cash. Realized and unrealized gains and losses are included in the accompanying statements of activities and changes in net assets. Money market accounts that are held in a portfolio at the same institution as other investments are classified as investments.

#### *Accounts Receivable*

Accounts receivable consist primarily of amounts due from various sponsorships. The balance of accounts receivable was \$463,106 and \$1,628 for the years ended June 30, 2021 and 2020, respectively. Accounts receivable as of June 30, 2021 represents sponsorships for the PFF Summit, PFF Events, corporate partnerships, and miscellaneous receivables of \$210,000, \$45,000, \$199,649, and \$8,457, respectively. Accounts receivable as of June 30, 2020, represents \$1,628 of miscellaneous receivables.

# Pulmonary Fibrosis Foundation

## Notes to Financial Statements

---

### ***Contributions Receivable***

Contributions that are mailed by the donor before year-end, but not received until after year-end, are included as contributions receivable.

### ***Pledges Receivable***

Unconditional promises to give are recognized as revenues or gains in the period received and as assets depending on the form of the benefits received. Conditional promises to give are recognized only when the conditions on which they depend are substantially met and the promises become unconditional. Pledges receivable are amounts committed by donors that have not been received by the Organization. These amounts are classified as net assets with donor restrictions until received.

### ***Contract Receivable***

Contract receivable represents fee for service agreements between the Organization and various companies related to Accounting Standards Codification (ASC) 606 revenue contracts. As of June 30, 2021, contract receivable was \$1,040,366, which represents fee for service agreements for the PFF Registry of \$858,241 and various corporate partnerships of \$182,125. For comparability, the prior year accounts receivable of \$32,369 was recategorized as contract receivable, representing revenue from a corporation.

### ***Other Receivables***

The Organization agreed to make a prepayment of \$375,000 to the Data Coordinating Center (DCC) of the PFF Registry in June of 2016, to provide sufficient funds for ongoing site activity payments made by the DCC, which would be reimbursed by the Organization. The prepayment could only be used to pay site costs as described in the agreement and any unused portion would be refunded upon contract termination. The original contract was extended to October 2023 and therefore this prepayment has been categorized as a long-term receivable as of June 30, 2021.

### ***Allowance for Doubtful Accounts***

The Organization recognizes an allowance for losses on accounts, contributions, pledges, contracts, and sponsorships receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical bad-debt experience, current receivables aging, and expected future write-offs, as well as an assessment of specific identifiable customer accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recognized as program expense in the statements of functional expenses. There was no allowance for doubtful accounts as of June 30, 2021 or 2020.

### ***Property and Equipment***

Property and equipment are recorded at cost if purchased or fair value at the date of donation. Depreciation is computed using the straight-line method over three to five years for computer hardware and software, and five to seven years for equipment and fixtures. The Organization follows the practice of capitalizing all expenditures for property and equipment in excess of \$500. When property and equipment are retired or otherwise disposed of, the costs and related accumulated

# Pulmonary Fibrosis Foundation

## Notes to Financial Statements

---

depreciation are removed from the respective accounts and any gain or loss on disposition is credited or charged to operations. Maintenance and repairs are expensed as incurred.

### ***Intangibles***

Intangible assets consist of website development and trademark costs. Two additional website projects are currently under development. Under ASC 350, these costs are recognized as an intangible asset and are amortized using the straight-line method over periods between three and ten years. Amortization expense is expected to be \$162,458 for the next three years for the website and microsites; the trademark amortization expense is expected to be \$62,364 over the next ten years.

### ***Goodwill***

On November 19, 2015, the Organization acquired all rights to the Daughters of Pulmonary Fibrosis program (the Daughters program) from the Coalition for Pulmonary Fibrosis (CPF). The Organization cultivated the Daughters program as one of their educational programs, with an expanded focus on identifying and developing resources for the caregiver community. The cost of the goodwill purchased was \$55,000 to be amortized over the next ten years using the straight-line method at the rate of \$5,500 per year. Goodwill amortization was \$5,500 for both of the years ended June 30, 2021 and 2020. During this fiscal year, funding for the Daughters program was exhausted and therefore the program was dissolved as the Organization redirected these activities into other programs. The remaining goodwill was written off resulting in a loss on disposal of \$23,833. Accumulated amortization as of June 30, 2021 and 2020 was \$0 and \$25,667, respectively.

### ***Grants Payable***

Grants payable consists of awards to universities and hospitals for research purposes, which are recognized as expense when they are awarded.

### ***Accrued Liabilities***

Accrued liabilities are made up of various expenses, including payroll, medical team-related liabilities, consulting, legal fees, PFF Registry site payment fees, and Data Coordinating Center costs that relate to the years ended June 30, 2021 and 2020.

### ***Deferred Rent***

Rent expense on non-cancelable leases containing known future scheduled rent increases or free rent periods is recorded on a straight-line basis over the respective lease term. The lease term begins when the Organization has right to control the use of the leased property and includes the initial non-cancelable lease term plus any periods covered by renewal options that the Organization is reasonably assured of exercising. The difference between rent expense and rent paid is accounted for as deferred rent and is amortized over the lease term. For the year ended June 30, 2021, the deferred rent liability was \$15,259 and was included in accrued liabilities. For the year ended June 30, 2020, the deferred rent asset was \$13,518 and was included in other assets on the statements of financial position.

# Pulmonary Fibrosis Foundation

## Notes to Financial Statements

---

### ***Net Assets***

The net assets of the Organization are classified as follows:

*Net Assets Without Donor Restrictions* - Net assets without donor restrictions represent the portion of expendable net assets that are available for operations, which includes net assets designated by the Board for general operating purposes. The Board-Designated Operating Reserves are intended to provide an internal source of funds for situations, such as a sudden increase in expenses, one-time unbudgeted expenses, unanticipated loss in funding, or uninsured losses. The Board-Designated Operating Reserves are to be used and replenished within a reasonably short period of time.

*Net Assets with Donor Restrictions* - Net assets with donor restrictions represent the portion of net assets that are subject to donor-imposed restrictions related to a time restraint or for a specific use, such as educational materials, legislative advocacy, outreach and awareness, the PFF Care Center Network, PFF Registry, PFF Summit, program support, research grants, support groups, and PFF events. Satisfaction of net assets with donor restrictions (i.e. when the donor-stipulated purpose has been fulfilled or the stipulated time period has elapsed) is reported as a reclassification from net assets with donor restrictions to net assets without donor restrictions. Some assets with donor restrictions may include a stipulation that assets provided be maintained permanently (perpetual in nature) while permitting the Organization to expend the income generated by the assets in accordance with the provisions of additional donor restrictions and the release of restrictions, respectively. The Organization had no assets that are perpetual in nature as of June 30, 2021 and 2020.

### ***Revenue from Contracts with Customers***

On July 1 2020, the Organization adopted Financial Accounting Standards Board (FASB) ASC 606, *Revenue from Contracts with Customers* (ASC 606), using the modified retrospective method applied to those contracts that were not fully satisfied as of July 1, 2020. The core principle of ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Organization expects to be entitled for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, requires judgement and estimation within the revenue recognition process. Results for reporting periods beginning after July 1, 2020 are presented under ASC 606, while prior-period amounts are not adjusted and continue to be reported in accordance with historic accounting under ASC 605. The adoption of ASC 606 resulted in a cumulative adjustment recorded to beginning net assets on July 1, 2020 of \$749,896. Accordingly, comparative information in the Organization's financial statements has not been restated and continues to be reported under the accounting standards in effect for those periods.

The Organization discloses receivables from contracts with customers separately in the statements of financial position. The timing of revenue recognition, billings, and cash collections results in receivables, contract assets, and contract liabilities. Billing may occur subsequent to revenue recognition, resulting in contract assets. Most times the Organization receives advances or deposits from customers before the revenue is recognized, resulting in contract liabilities. Accounts receivable are recorded when the right to the consideration becomes unconditional and are presented separately in the statement of financial position as contract receivable. Contract assets are included in other assets and contract liabilities are in deferred revenue.



# Pulmonary Fibrosis Foundation

## Notes to Financial Statements

The impact of the cumulative effect adjustment on the statement of financial position upon adoption was as follows:

	As of June 30, 2020	Cumulative Effect Adjustment	As of July 1, 2020
<b>Liabilities and Net Assets</b>			
<b>Current Liabilities</b>			
Deferred revenue	\$ 1,207,629	\$ (749,896)	\$ 457,733
<b>Total Current Liabilities</b>	<b>3,034,674</b>	<b>(749,896)</b>	<b>2,284,778</b>
<b>Total Liabilities</b>	<b>3,594,974</b>	<b>(749,896)</b>	<b>2,845,078</b>
<b>Net Assets</b>			
Without donor restrictions	4,012,393	749,896	4,762,289
<b>Total Net Assets</b>	<b>7,297,830</b>	<b>749,896</b>	<b>8,047,726</b>
<b>Total Liabilities and Net Assets</b>	<b>\$ 10,892,804</b>	<b>\$ -</b>	<b>\$ 10,892,804</b>

The impact of adoption on the Organization's statement of financial position and statement of activities as of and for the year ended June 30, 2021:

	As Reported Under ASC 606	Effect of Adoption	As Computed Under ASC 605
<b>Statement of Financial Position</b>			
<b>Liabilities and Net Assets</b>			
<b>Current Liabilities</b>			
Deferred revenue	\$ 2,437,790	\$ 1,167,193	\$ 3,604,983
<b>Total Current Liabilities</b>	<b>4,852,634</b>	<b>1,167,193</b>	<b>6,019,827</b>
<b>Total Liabilities</b>	<b>5,433,309</b>	<b>1,167,193</b>	<b>6,600,502</b>
<b>Net Assets</b>			
Without donor restrictions	6,584,930	(1,167,193)	5,417,737
<b>Total Net Assets</b>	<b>9,312,283</b>	<b>(1,167,193)</b>	<b>8,145,090</b>
<b>Total Liabilities and Net Assets</b>	<b>\$ 14,745,592</b>	<b>\$ -</b>	<b>\$ 14,745,592</b>
<b>Statement of Activities and Changes in Net Assets</b>			
<b>Revenues, Gains, and Other Support</b>			
Program Service Fees	\$ 2,908,697	\$ (417,297)	\$ 2,491,400
<b>Total Revenues, Gains, and Other Support</b>	<b>10,274,036</b>	<b>(417,297)</b>	<b>9,856,739</b>
<b>Change in Net Assets</b>	<b>1,264,557</b>	<b>(417,297)</b>	<b>847,260</b>
<b>Net Assets, beginning of year</b>	<b>8,047,726</b>	<b>(749,896)</b>	<b>7,297,830</b>
<b>Net Assets, end of year</b>	<b>\$ 9,312,283</b>	<b>\$ (1,167,193)</b>	<b>\$ 8,145,090</b>

# Pulmonary Fibrosis Foundation

## Notes to Financial Statements

---

### *Revenue Recognition*

Revenue streams that meet the definition of an exchange transaction and fall within the scope of Topic 606 are: program service fees and special event ticket revenue.

### *Program Service Fees*

Under Topic 606, the Organization recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, the Organization performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when the Organization satisfies the performance obligation. The Organization only applies the 5-step model to contracts when it is probable that it will collect consideration it is entitled to in exchange for the goods or services it transfers to customers.

Revenue can be either recognized at a point in time or over a period of time. ASC 606 lays out three criteria for determining whether the revenue should be recognized over time. If the contract meets any one of these three, the revenue is recognized over time.

- The customer simultaneously receives and consumes the benefits.
- The Organization's performance creates or enhances an asset that the customer controls.
- The Organization's performance does not create an asset with an alternative use to the Organization and the Organization has an enforceable right to payment for the performance completed to date.

If none of the above are true, then revenue must be recognized at a point in time.

Revenues measured over time are recognized as the Organization makes progress towards fulfilling the performance obligation. The Organization must choose a method to measure the progress in completing the contract. The chosen method may be based on either outputs or inputs. An output method looks at the fair market value of goods and services transferred to the customer to date. An input method will be based on the costs of labor and materials as the Organization incurs them. There are two primary performance obligations in a majority of contracts with customers. One performance obligation is the Registry stand-ready obligation, which grants customers access to the Registry data along with continual project management by the Organization to maintain the Registry. This type of performance obligation is recognized over time on a pro rata monthly amount over the contract term. The other performance obligation is delivery of certain research studies, which is the delivery of a set of data from the Registry that can be used to complete study projects by the customer. This type of performance obligation is recognized in a point-in-time when the study data is delivered to the customer.

# Pulmonary Fibrosis Foundation

## Notes to Financial Statements

Below is a comparison of point in time versus over time revenue recognition as of June 30, 2021:

	Point in Time	Over Time	Total
Program Service Fees	\$ 545,270	\$ 2,363,427	\$ 2,908,697

### *Deferred Revenue*

The Organization's contract liabilities consist of program service fees from companies and universities, which are referred to as deferred revenue. The amounts received are recorded as deferred revenue until the Organization satisfies its performance obligations outlined in the agreements. Depending on the nature of the performance obligation, revenue can be recognized on a pro rata basis over the term of the agreement as the underlying performance obligation is satisfied or be recognized at a point in time when that performance obligation is met.

A summary of significant changes to the deferred revenue balance during fiscal year 2021 is shown below.

Balance, June 30, 2020	\$ 1,207,629
Cumulative effect adjustment of adopting ASC 606 on July 1, 2020	(749,896)
Amounts received in fiscal year 2021	4,888,754
Revenue recognized upon completion of performance obligations	(2,908,697)
<b>Balance, June 30, 2021</b>	<b>\$ 2,437,790</b>

### *Special Events Revenue*

Special event ticket revenue consists of both a contribution and an exchange transaction. The portion of the ticket price that corresponds to the value of the goods and services received by the attendee is considered an exchange transaction. The purchase of the event ticket is considered a contract between the Organization and the purchaser, as there is a right to enforce the contract for both parties and the Organization expects to collect the full amount it is entitled to, as the tickets are purchased in advance of the event. The Organization typically provides food and entertainment as part of the ticket price; these are not distinct within the context of the contract and therefore represent a single performance obligation. The fee for the ticket represents the transaction price and as there is only one performance obligation the entire price of the ticket is allocated to the performance obligation. The revenue is recognized at a point in time when the event takes place. Because events during the year ended June 30, 2021 were held virtually, there was no exchange transaction and all revenue was deemed to be a contribution.

### *Contributions and Sponsorships*

Contributions or sponsorships received are recorded as net assets without donor restrictions or net assets with donor restrictions, depending on the existence and/or nature of any donor restrictions and follows Topic 958. Support that is restricted by the donor is reported as an increase in net assets without restrictions if the restriction expires in the reporting period in which the support is recognized. All other donor-restricted support is reported as an increase in net assets with donor restrictions, depending on the nature of the restriction. When a restriction expires—that is, when a stipulated time restriction ends or purpose restriction is accomplished—net assets with donor

# Pulmonary Fibrosis Foundation

## Notes to Financial Statements

---

restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities and changes in net assets as net assets released from restrictions.

### ***In-Kind Contributions***

Contributions of services are recognized at a point in time if they create or enhance a non-financial asset or represent specialized skills that would be purchased if they were not donated. During the year ended June 30, 2021 and 2020, the Organization received donated software amounting to \$916 and \$335, respectively.

### ***Net Investment Return***

The Organization holds various investments in mutual funds, equities, and money market funds. The related fees from these investments are netted against investment income (see Note 2).

### ***Income Taxes***

The Organization is exempt from income taxes under Section 501(c)(3) of the Internal Revenue Code (IRC), except for net income derived from unrelated business activities. In addition, the Organization qualifies for the charitable contribution deduction under Section 170(b)(1)(A) and has been classified as an organization other than a private foundation under IRC Section 509(a).

The Organization's income tax filings are subject to audit by various taxing authorities. In evaluating the Organization's activities, management believes its position of tax-exempt status is based on current facts and circumstances, and there have been no uncertain positions taken related to recording income taxes. The Organization maintains an employee commuter benefits plan, under which benefits are deemed to be unrelated business income as of January 1, 2018. However, on December 20, 2019, the president signed into law a provision that would repeal the unrelated business income tax (UBIT) on qualified transportation fringe benefits. Accordingly, the Organization is expecting a refund of \$11,461 from prior UBIT payments.

It is the policy of the Organization to include in management and general expenses penalties and interest assessed by income taxing authorities. There are no penalties or interest from taxing authorities included in management and general expenses for the year ended June 30, 2021. There were penalties of \$133 and interest of \$18 from taxing authorities included in management and general expenses for the year ended June 30, 2020.

### ***Functional Allocation of Expenses***

In the statements of functional expenses, the costs that are directly associated with a particular program or supporting service are charged to that functional category such as travel, consulting, advertising, outside services, processing fees, printing, event expenses, grants, shop PFF merchandise, and legal fees. Additionally, certain costs have been allocated among the programs and supporting services benefited based on staff time devoted to the functional areas such as salaries and wages, employee benefits, payroll taxes, accounting fees, depreciation and amortization, dues and subscriptions, insurance, meetings and conferences, miscellaneous expenses, occupancy, office supplies, postage, rent, software subscriptions, and telephone expenses. The statements of functional expenses present natural classification detail of expenses by function.

# Pulmonary Fibrosis Foundation

## Notes to Financial Statements

---

### ***Adoption of New Accounting Principal***

On July 1 2020, the Organization adopted FASB ASC 606, *Revenue from Contracts with Customers* (ASC 606), using the modified retrospective method applied to those contracts that were not fully satisfied as of July 1, 2020. See Revenue from Contracts with Customers section above for further information on impact of the implementation of ASC 606.

### ***Recent Accounting Pronouncements***

In February 2016, the FASB issued ASU 2016-02, *Leases (Topic 842)*. This update, along with ASU 2018-10, *Codification Improvements to Topic 842: Leases*, ASU 2018-11, *Leases (Topic 842): Targeted Improvements* and ASU 2018-20, *Leases (Topic 842): Narrow-Scope Improvements for Lessors*, establishes a comprehensive leasing standard. These updates require the recognition of lease assets and lease liabilities on the statements of financial position and disclosure of key information about leasing arrangements for lessees and lessors. The new standard applies a right-of-use (ROU) model that requires, for leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset for the lease term and a liability to make lease payments to be recorded. The guidance also expands the required quantitative and qualitative lease disclosures as well as provides entities with an additional (and optional) transition method to adopt the new standard. The FASB issued ASU 2015-14, which deferred the effective date for the Organization until annual periods beginning after December 15, 2021. Earlier adoption is permitted. The Organization is currently evaluating the impact of this ASU on its financial statements.

In September 2020, the FASB issued ASU 2020-07, *Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets (Topic 958)*. This update addresses presentation and disclosure of contributed nonfinancial assets. This update will require a nonprofit to present contributed nonfinancial assets as a separate line item in the statements of activities, apart from contributions of cash and other financial assets, and to disclose contributed nonfinancial assets recognized within the statements of activities disaggregated by category that depicts the type of contributed nonfinancial assets, and for each category of contributed nonfinancial assets recognized to include the following: qualitative information about whether the contributed nonfinancial assets were either monetized or utilized during the reporting period (if utilized, disclose a description of the programs or other activities in which those assets were used), the Organization's policy (if any) about monetizing rather than utilizing contributed nonfinancial assets, a description of any donor-imposed restrictions associated with the contributed nonfinancial assets, a description of the valuation techniques and inputs used to arrive at a fair value measure at initial recognition, and the principal market used to arrive at a fair value measure if it is a market in which the recipient Organization is prohibited by a donor-imposed restriction from selling or using the contributed nonfinancial assets. The ASU is to be applied on a retrospective basis and effective for annual periods beginning after June 15, 2021, and interim periods within annual periods beginning after June 15, 2022. Earlier adoption is permitted. The Organization is currently evaluating the impact of this ASU on its financial statements.

### ***Subsequent Events***

The Organization entered into a Registry Collaboration Agreement in July 2021 to receive \$1,800,000 over a three-year period. Revenue for this contract will be recognized per ASC 606.

# Pulmonary Fibrosis Foundation

## Notes to Financial Statements

In October 2021, the Organization received a combination stock and cash donation of \$1,057,000 from a family as a memorial to a family member of which 75% of the gift will be directed to research and 25% will be directed to education.

In January 2022, the Organization received written confirmation of an unrestricted stock and cash bequest valued at approximately \$1,500,000.

Subsequent events were evaluated through February 16, 2022, which is the date the financial statements were available to be issued. Other than the matters disclosed above, no other matters were identified.

## 2. Fair Value Measurements

FASB ASC 820, *Fair Value Measurements and Disclosures*, provides the framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows:

*Level 1* - This level consists of quoted prices in active markets for identical investments.

*Level 2* - This level consists of other significant observable inputs (including quoted prices for similar investments, interest rates, credit risk, etc.).

*Level 3* - This level consists of significant unobservable inputs (including assumptions in determining the fair value of investments).

The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. There were no changes in valuation methodologies during the years ended June 30, 2021 and 2020.

Fair values of assets measured on a recurring basis were as follows:

### *June 30, 2021*

	Level 1	Level 2	Level 3	Total
Money market	\$ 2,086,095	\$ -	\$ -	\$ 2,086,095
Mutual funds	3,463,390	-	-	3,463,390
<b>Total</b>	<b>\$ 5,549,485</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 5,549,485</b>

### *June 30, 2020*

	Level 1	Level 2	Level 3	Total
Money market	\$ 1,896,450	\$ -	\$ -	\$ 1,896,450
Fixed-income CDs	250,630	-	-	250,630
Mutual funds	2,716,643	-	-	2,716,643
<b>Total</b>	<b>\$ 4,863,723</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 4,863,723</b>

# Pulmonary Fibrosis Foundation

## Notes to Financial Statements

---

### 3. Concentrations of Credit Risk

The Organization maintains the majority of its cash at several financial institutions. All deposit accounts at Federal Deposit Insurance Corporation (FDIC)-insured institutions are insured up to \$250,000. At times during the year, the Organization's bank balances may have exceeded the federally insured limits; however, it has not experienced any losses with respect to its bank balances in excess of government provided insurance.

Investments in certificates of deposit at FDIC-insured institutions are insured up to \$250,000 per institution.

The Organization maintains reserve cash at a brokerage firm. This account is insured by the Securities Investor Protection Corporation up to \$500,000, including a maximum of \$250,000 for claims for cash, and additional coverage is provided by the brokerage firm. At June 30, 2021 and 2020, the Organization had no uninsured cash investment balances at brokerage firms.

For the years ended June 30, 2021 and 2020, 51% and 36%, of total revenue was from three and two sources, respectively. This is the result of contracts executed with two of the organizations in October and November of 2015 for multi-year funding of the PFF Registry, the PFF Care Center Network, and associated programs. These contracts contain multiple revenue types, portions of which are fee-for-service specific to the PFF Registry and other portions, which are sponsorship revenues, related to the PFF Care Center Network and associated programs. The total of these original agreements exceeds \$20 million and were received over a period of five years. This funding has allowed the Organization to increase the PFF Care Center Network to 68 sites, perform various educational programming within the network, and identify the patients targeted for the PFF Registry.

The PFF will continue to operate the PFF Registry beyond the initial five-year period. To support this continued effort the Organization has secured \$6 million of new funding from multiple sources to cover project expenses over the next three years.

As of June 30, 2021, the Organization has received contributions from a private funder that represents 5% of total revenue to provide program support, as well as funding to support an Innovation Challenge in pulmonary fibrosis. As of June 30, 2020, the same funder provided 17% of total revenue for a marketing and awareness campaign.

The board and management were aware of these concentrations of credit risk when approving these projects and planned for this. The Organization is increasing other revenue streams to diversify the funding of the PFF Registry. The board and management felt that the benefit to research and the patient community outweighed the concentration of credit risk sensitivity in the earlier stages of the project.

### 4. Related-Party Transactions

Included in contributions on the statements of activities and changes in net assets is \$63,733 and \$56,009 from board members for the years ended June 30, 2021 and 2020, respectively.

# Pulmonary Fibrosis Foundation

## Notes to Financial Statements

### 5. Property and Equipment

The Organization's property and equipment was as follows:

<i>June 30,</i>		2021		2020
Computer hardware and software	\$	221,720	\$	223,703
Less: accumulated depreciation		(176,349)		(180,713)
<b>Total</b>	<b>\$</b>	<b>45,371</b>	<b>\$</b>	<b>42,990</b>

Depreciation expense for the years ended June 30, 2021 and 2020 was \$27,802 and \$36,823, respectively.

### 6. Intangible Assets

The Organization's intangible assets were as follows:

<i>June 30,</i>		2021		2020
Assets in progress	\$	34,650	\$	72,322
Trademarks		69,129		21,392
Website development		267,626		133,406
Other intangibles		5,000		-
Less: accumulated amortization		(116,933)		(83,557)
<b>Intangibles, Net</b>	<b>\$</b>	<b>259,472</b>	<b>\$</b>	<b>143,563</b>

Amortization expense for the years ended June 30, 2021 and 2020 was \$33,376 and \$13,551, respectively.

### 7. Accrued Liabilities

Accrued liabilities consist of the following:

<i>June 30,</i>		2021		2020
PFF Registry site payments	\$	1,125,361	\$	1,101,061
Other accrued expenses		16,506		77,933
Medical team expenses		85,756		69,797
Payroll and related benefits		73,609		40,656
Deferred rent		15,259		13,518
<b>Total Accrued Liabilities</b>	<b>\$</b>	<b>1,316,491</b>	<b>\$</b>	<b>1,302,965</b>

### 8. Paycheck Protection Program Loan

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the CARES Act) was signed into law. The CARES Act appropriated funds for the SBA Paycheck Protection Program (PPP) loans that are forgivable in certain situations to promote continued employment to provide liquidity to small businesses harmed by COVID-19. In April 2020, the Organization applied for and received funds under the PPP in the amount of \$560,300. In December, 2020, the Organization was granted full forgiveness for their initial PPP loan in the amount of \$560,300 and it is included in other



# Pulmonary Fibrosis Foundation

## Notes to Financial Statements

---

revenues on the statement of activities and changes in net assets. In March 2021, the Organization applied for and received a second round of PPP loan funding in the amount of \$580,675, which is included in Paycheck Protection Program loan on the statement of financial position as of June 30, 2021.

The application for these funds requires the Organization to, in good faith, certify that the current economic uncertainty made the loan request necessary to support the ongoing operations of the Organization. This certification further requires the Organization to take into account the current business activity and ability to access other sources of liquidity sufficient to support ongoing operations in a manner that is not significantly detrimental to the business. The receipt of these funds, and the forgiveness of the loan attendant to these funds, is dependent on the Organization having initially qualified for the loan and qualifying for the forgiveness of such loan based on future adherence to the forgiveness criteria. As such, there are uncertainties surrounding the extent to which the Organization may be eligible for loan forgiveness, but management continues to analyze and monitor the criteria under the program.

The loan has an interest rate of 1.0% and matures five years from the issuance date. Principal payments and interest are deferred until the date that the amount of forgiveness is remitted to the lender. If the Organization has not applied for forgiveness within ten months after the last day of the covered period, payments of principal and interest will begin.

### 9. Net Assets

#### *Without Donor Restrictions*

Net assets without donor restrictions were as follows:

<i>June 30,</i>	2021	2020
Board-designated operating reserves	\$ 3,912,525	\$ 3,089,215
General	2,672,405	923,178
<b>Total</b>	<b>\$ 6,584,930</b>	<b>\$ 4,012,393</b>

#### *With Donor Restrictions*

The following items were net assets with donor restrictions due to either use or time restrictions:

<i>June 30,</i>	2021	2020
Education	\$ 925,778	\$ 1,134,319
Legislative Advocacy	50,000	-
Other	433,865	181,853
Outreach and awareness	265,679	518,477
PFF Care Center Network	253,715	756,782
PFF Registry	399,252	77,877
PFF Summit	90,279	-
Research grants	76,630	492,043
Support groups	232,155	124,086
<b>Total</b>	<b>\$ 2,727,353</b>	<b>\$ 3,285,437</b>

# Pulmonary Fibrosis Foundation

## Notes to Financial Statements

The following items were released from net assets with donor restrictions and reclassified to net assets without donor restrictions due to meeting either use or time restrictions:

<i>June 30,</i>	2021	2020
Education	\$ 602,196	\$ 545,013
Other	181,853	170,009
Outreach and awareness	277,798	302,893
PFF Care Center Network	503,067	584,654
PFF Registry	77,877	436,640
PFF Summit	-	636,508
Program support	-	375,000
Research grants	455,925	175,000
Support groups	86,056	151,464
	2,184,772	3,377,181
<b>Transfer Due to Donor Intent Change*</b>	<b>(355,825)</b>	-
<b>Total</b>	<b>\$ 1,828,947</b>	<b>\$ 3,377,181</b>

\* During the year ended June 30, 2021, there was a change in donor intent for a contribution made during fiscal year 2020. The change shifted the restriction of net assets from Research Grants to PFF Registry for approximately \$356,000. The transfer is included in net asset releases for the Research Grants to move the restriction to the PFF Registry. As this is not a true release, a line is included above to add back the release to properly reflect the amount of net asset releases presented on the statement of activities and changes in net assets.

### 10. Lease Obligation and Rental Expense

The Organization entered into a lease agreement for office space at 230 East Ohio Street, Suite 500, Chicago, Illinois, commencing August 1, 2016 and extending through November 2022. Rental expense on all leases for the years ended June 30, 2021 and 2020 was \$250,687 and \$250,622, respectively. The Organization is also liable for its proportionate share of property taxes, increased expenses, insurance, utilities, and repairs.

The estimated future minimum rental and lease obligation for the succeeding years under non-cancelable operating leases is as follows:

<i>Year ending June 30,</i>	
2022	\$ 250,927
2023	115,104
<b>Total</b>	<b>\$ 366,031</b>

# Pulmonary Fibrosis Foundation

## Notes to Financial Statements

### 11. Commitments

The Organization has entered into agreements with hotels to hold future events. The agreements include penalties if the Organization breaks the contract. No provision has been made in the financial statements for any contingency relating to the commitments. The Organization made the following commitments for hotel space (includes hotel room cancellation fees):

November 2021 - PFF Summit, Virtual	\$	132,200
November 2023 - PFF Summit, Orlando, FL		287,016
November 2025 - PFF Summit, Chicago, IL		117,752
<b>Total</b>	<b>\$</b>	<b>536,968</b>

### 12. Special Events

Revenues and expenses from special events are shown at the gross amounts in the statements of activities and changes in net assets. Gross revenue and expense for each event was as follows for the years ended June 30, 2021 and 2020:

Event	Without Donor Restrictions	With Donor Restrictions	Total Revenue	Expense	Net
PFF Walk FY20-21	\$ 460,575	\$ -	\$ 460,575	\$ 341,175	\$ 119,400
PFF Walk FY20-21	-	224,216	224,216	-	224,216
Broadway Belts! FY20-21	354,085	-	354,085	197,354	156,731
<b>Total Revenue FY20-21</b>	<b>\$ 814,660</b>	<b>\$ 224,216</b>	<b>\$ 1,038,876</b>	<b>\$ 538,529</b>	<b>\$ 500,347</b>

Event	Without Donor Restrictions	With Donor Restrictions	Total Revenue	Expense	Net
PFF Walk FY19-20	\$ 620,657	\$ -	\$ 620,657	\$ 401,394	\$ 219,263
PFF Walk FY19-20	-	146,853	146,853	-	146,853
Broadway Belts! FY19-20	392,192	-	392,192	239,464	152,728
<b>Total Revenue FY19-20</b>	<b>\$ 1,012,849</b>	<b>\$ 146,853</b>	<b>\$ 1,159,702</b>	<b>\$ 640,858</b>	<b>\$ 518,844</b>

As of June 30, 2021 and 2020, the PFF Walk Program was comprised of PFF Walks in the following cities: Chicago, New York City, the District of Columbia, Dallas, and San Francisco. Net assets with donor restrictions for the fiscal year 2021 PFF Walk of \$146,853 were reflected on fiscal year 2020's financial statements as net assets with donor restrictions and released in fiscal year 2021. Net assets with donor restrictions for the fiscal year 2020 PFF Walks and Broadway Belts! of \$139,939 were reflected on fiscal year 2019's financial statements as net assets with donor restrictions and released in fiscal year 2020. Restrictions on these funds are related to timing of the event or receipt of the funds.

Broadway Belts remains a PFF special event. During the years ended June 30, 2021 and 2020, the Organization also had third parties hold special events in honor of the Organization. The net proceeds of each event are remitted by the third parties to the Organization after the event has been completed. These proceeds are recorded as contributions as the events are not held by the Organization.

# Pulmonary Fibrosis Foundation

## Notes to Financial Statements

---

### 13. Retirement Plan

The Organization provides a 401(k) salary reduction plan that covers all full-time employees and part-time employees who work 1,000 hours in a single year. Contributions are made by the employees at an amount or percentage of their salary not to exceed applicable Internal Revenue Service limits. The Organization contributes 3% of the employee's base salary into the Plan, irrespective of the employee's level of deferral. The Organization made employer contributions to the plan of \$102,740 and \$94,807 for the years ended June 30, 2021 and 2020, respectively.

### 14. Liquidity and Availability

The Organization's financial assets available within one year of the statements of financial position date for general expenditures are computed as follows:

<i>June 30,</i>	<b>2021</b>	<b>2020</b>
Total assets at year end	\$ 14,745,592	\$ 10,892,804
Less: nonfinancial assets:		
Prepaid expenses and other assets	507,279	137,343
Property and equipment	45,371	42,990
Other receivables - long-term	375,000	375,000
Deposits	56,631	56,631
Intangibles, net	259,472	143,563
Goodwill, net	-	29,333
<b>Total Financial Assets Available Within One Year</b>	<b>13,501,839</b>	<b>10,107,944</b>
Less:		
Assets included above, which are restricted to cover programmatic expenses in the next year:		
Restricted by donors with time or purpose restrictions	2,727,353	3,285,437
Deferred revenue	2,437,790	1,207,629
<b>Total Assets Restricted for Programmatic Expenses</b>	<b>5,165,143</b>	<b>4,493,066</b>
<b>Total Financial Assets Available to Management for General Expenditures Within One Year</b>	<b>\$ 8,336,696</b>	<b>\$ 5,614,878</b>

The Organization maintains a policy of structuring its financial assets to be available as its general expenditures, liabilities, and other obligations come due. The Organization has been building its liquid assets to ensure the stability of the mission, programs, employment, and ongoing operations of the Organization. Long-term investments are available for use should the Organization deem them necessary; however, the investments are not expected to be used within one year. As of June 30, 2021, management feels that it has a sufficient cash balance, when including the amounts restricted to cover programmatic expenses in the next year, to meet its cash needs for general expenditures within one year. Board-designated net assets are available for operations, as needed, and therefore are not included as a reduction to arrive at the total financial assets available to Management for general expenditures.